Public health detailing to increase naloxone access in NYC pharmacies

J Am Pharm Assoc (2003). 2023 May-Jun;63(3):885-892. doi: 10.1016/j.japh.2023.03.001. Epub 2023 Mar 9.

Abstract

Background: Drug overdose is a public health crisis in the United States. Opioid overdose deaths are preventable using naloxone, an opioid antagonist that reverses the effect of an opioid and prevents fatal overdose.

Objectives: This study aimed to evaluate changes in naloxone standing order status, attitudes, and practice behavior after an 8-week public health detailing campaign on increasing naloxone access conducted among pharmacists in independent pharmacies in New York City (NYC).

Methods: Campaign recommendations were to (1) enroll in the NYC pharmacy naloxone standing order program, (2) offer naloxone to at-risk patients, and (3) educate patients on how to use naloxone. Evaluation was performed using initial and follow-up surveys administered to pharmacists during detailing visits and Department of Health and Mental Hygiene data on pharmacies in the standing order program.

Results: Detailing visits were completed with 1153 pharmacists; follow-up visits were completed with 457 (40%). Self-reported attitudes and practice behavior related to the 3 campaign recommendations improved (P < 0.01). After the campaign, 519 new pharmacies enrolled in the standing order program.

Conclusions: The detailing campaign substantially increased the number of pharmacies enrolled in the standing order program and was associated with improved attitudes and practice behavior related to naloxone provision to varying degrees. Other jurisdictions could consider detailing pharmacists as a strategy to increase naloxone access.

MeSH terms

  • Drug Overdose* / drug therapy
  • Drug Overdose* / prevention & control
  • Humans
  • Naloxone / therapeutic use
  • Narcotic Antagonists / therapeutic use
  • New York City
  • Opioid-Related Disorders* / complications
  • Opioid-Related Disorders* / drug therapy
  • Opioid-Related Disorders* / prevention & control
  • Pharmacies*
  • Pharmacists
  • Self Report
  • United States

Substances

  • Naloxone
  • Narcotic Antagonists